Evidence map›Paper›PMID 27587244›Full record

Observational studyZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2016

[Comparison of immune reconstitution at early stage after unmanipulated haploidentical stem cell transplantation between high- and standard- risk Philadelphia chromosome- negative acute lymphoblastic leukemia patients in CR1].

Z L Bian, Y J Chang, L P Xu, Y Wang, X H Zhang, K Y Liu, X J Huang

Abstract readObservational Study
In one paragraph

Observational study in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Z L BianPeking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Diseases, Beijing 100044, China.
Y J Chang
L P Xu
Y Wang
X H Zhang
K Y Liu
X J Huang

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo compare the early stage immune reconstitution of high- and standard-risk Philadelphia chromosome- negative acute lymphoblastic leukemia (ALL) CR1 patients who had haploidentical blood and marrow stem cell transplantation (HBMT).

methodsA total of 49 Ph-negative ALL CR1 patients who received HBMT and had complete early stage immune reconstitution data(+30, +60 and +90 d post transplantation) from Jan. 2010 to Dec. 2012 were enrolled. Immunophenotyping for B and T lymphocytes was performed post HBMT via flow cytometry. Fresh peripheral blood cells were stained with fluorochrome-labeled monoclonal antibodies against cluster of differentiation CD19, CD3, CD4, CD8, CD45RO, CD45RA and CD28. The early reconstitution of lymphocyte subsets, survival and prognosis between standard- risk group, high- risk adult group and high- risk children group were compared.

resultsThere were no significant differences in all these T lymphocyte subsets among three groups at the three check points (P>0.05). Moreover, at the same time, comparable outcome had been achieved between standard-risk group (n=18), high-risk adult group (n=16) and high-risk children group (n=15). There were no differences in 2- y relapse incidence (27.8% vs 31.3% vs 26.7%, P=0.957), 2- y non- relapse mortality (11.1% vs 0 vs 13.3%, P=0.185), 2- y leukemia free survival (61.1% vs 68.8% vs 60.0%, P=0.834) and overall survival (77.8% vs 68.8% vs 60.0%, P=0.529) among the three groups. Incidence of grade Ⅱ-Ⅳ aGVHD was 44.4% vs 12.5% vs 46.7% (P=0.075) and incidence of cGVHD was 61.1% vs 50.0% vs 40.0% (P=0.249).

conclusionComparison of immune reconstitution at early stage may be a reasonable cause to explain that equivalent outcomes were observed among high- and standard- risk Ph- negative ALL CR1 patients after HBMT.

Indexed as

HaplotypesPeripheral Blood Stem Cell TransplantationPhiladelphia ChromosomeAcute DiseaseAdultChildHematopoietic Stem CellsHematopoietic Stem Cell TransplantationHumansImmunophenotypingLymphocytesPrecursor Cell Lymphoblastic Leukemia-LymphomaPrognosisRecurrence

Identifiers

PMID27587244
PMCPMC7348535

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.